<DOC>
	<DOCNO>NCT01995825</DOCNO>
	<brief_summary>In study , brand name lamotrigine ( LAMICTAL ) generic lamotrigine compare patient epilepsy . Both brand name generic lamotrigine approve Food Drug Administration ( FDA ) commonly use treat epilepsy . Some physician patient epilepsy believe brand generic lamotrigine clinically significant difference efficacy tolerability . The brand name generic tablet show blood level measure healthy volunteer without epilepsy , drug yet compare patient epilepsy . This study comparison , switch patient brand generic structure manner , see drug , primarily term blood level . Other comparison also make secondarily , look difference adverse effect seizure control .</brief_summary>
	<brief_title>Lamotrigine Bioequivalence</brief_title>
	<detailed_description>As commonly do bioequivalence study , null hypothesis generic ( i.e . test ) bioINequivalent brand name ( i.e . reference ) . Hence , alternative hypothesis generic bioequivalent brand name .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Subject able provide inform consent . Subject male female 18 65 year age inclusive . Subject diagnosis epilepsy simple partial seizure and/or complex partial seizure , without secondary generalization primary generalized seizure . Subject history least one seizure and/or AED related adverse event AED change ; least one seizure and/or AED related adverse event 12 month prior Visit 1 . Subject maintain stable dose regimen antiepileptic drug ( AEDs ) , include lamotrigine 200mg , 400mg , 600mg total daily dosage divide BID least 28 day prior Visit 1 . Additionally , subject must take lamotrigine 8 week prior Visit 1 . Subject willing switch brand generic lamotrigine . Subject acceptable candidate venipuncture . Subject willing stop OTC medication 24 hour prior 12 hour study visit . Subject currently participate participate within last 2 month trial investigational drug experimental device . Subject history status epilepticus within 12 month period prior Visit 1 . Subject medical condition , opinion investigator , could jeopardize subject 's health would compromise subject 's ability participate trial . Subject psychiatric condition , opinion investigator , could jeopardize subject 's health would compromise subject 's ability participate trial confound interpretation trial data . Subject know hypersensitivity lamotrigine . Subject medical condition impact drug absorption ( e.g . gastric bypass surgery ) , include routine use ( i.e . daily weekly ) use acid blocker , antacid , antidiarrhea , stimulant , appetite suppressant , anti nausea medication drug modulate GI function . Subject history alcohol drug abuse within previous two year . Subject acute subacutely progressive CNS disease . Subject moderate severe liver impairment assess alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , total bilirubin level â‰¥5 time upper limit normal ( ULN ) . Subject moderate severe renal impairment assess creatinine clearance lower 50mL/min , use CockcroftGault formula . Female subject childbearing potential eligible participate unwilling unable use medically acceptable method contraception throughout entire study period one week study complete . Medically acceptable method contraception may use subject and/or partner : condom spermicide , diaphragm spermicide , IUD without progesterone , vaginal spermicidal suppository , surgical sterilization partner ( ) abstinence . Female subject pregnant nursing . Female subject use hormonal contraceptive precaution include progesteronecoated IUD . Subjects use hormonal replacement therapy . Subject unwilling unable maintain approximate daily smoking use study . Subject use rifampin nonAED strongly modulate lamotrigine level . In addition lamotrigine and/or vagus nerve stimulation and/or intermittent benzodiazepine use ( e.g . lorazepam , diazepam , clonazepam ) , subject take two concomitant AEDs . Subject willing able adherent study protocol ( e.g . dose lamotrigine interact comedication ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>bioequivalence</keyword>
	<keyword>lamotrigine</keyword>
	<keyword>epilepsy</keyword>
</DOC>